Losartan Potassium Tablet, Film Coated
Product Images NDC 65862-201

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 65862-201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Fig1

A line chart comparing the percentage of patients with the primary endpoint over study months between Atenolol and Losartan Potassium. The graph shows that Losartan Potassium has an adjusted risk reduction of 13% with a p-value of 0.021, illustrating a progression of patient outcomes over approximately 66 months.*

FDA Label Image

Losartan Fig2

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period for Atenolol and Losartan Potassium. The graph shows adjusted risk reduction of 25% with Losartan Potassium, with p=0.001, indicating statistical significance.*

FDA Label Image

Figure 3 (Losartan Fig3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' showing hazard ratios with 95% confidence intervals comparing Losartan Potassium and Atenolol event rates for primary composite events and stroke (fatal/non-fatal). The chart includes demographic breakdowns by age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). It illustrates the number of patients, event rates for both drugs, and the hazard ratios favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The graph shows cumulative event rates with Losartan Potassium having a lower percentage compared to placebo. Risk reduction noted as 16.1%, with statistical significance p=0.022.*

FDA Label Image

Losartan Fig5

Packaging label for Losartan Potassium Tablets USP 25 mg film-coated tablets by Aurobindo Pharma Limited. The label includes drug storage instructions, dosage instructions reference, distributor information (Aurobindo Pharma USA, Inc.), and package quantity of 90 tablets. It features a barcode and states the product is made in India.*

FDA Label Image

Losartan Fig6

Losartan Potassium Tablets USP 50 mg film-coated tablet label by Aurobindo Pharma Limited. The label includes dose strength, tablet count (30 tablets), storage instructions, distributor information (Aurobindo Pharma USA, Inc.), and NDC 65862-202-30.*

FDA Label Image

Losartan Fig7

Label for Losartan Potassium Tablets USP 100 mg film-coated tablets, labeler Aurobindo Pharma Limited. The label includes storage instructions, distributor information, and packaging details for a bottle of 30 tablets. It specifies Rx only and lists the NDC 65862-203-30.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of Losartan Potassium, showing its molecular formula with detailed structural elements and the potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.